ArthritisNCT00754416
S.E.S Shoulder Arthroplasty Data Collection
An observational study of Arthritis, run by Zimmer Biomet at 12 sites in 2 countries.
Trial summary
This observational study intends to collect efficacy and safety data on S.E.S shoulder system Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Arthritis
- How many people
- 100 participants
- Where
- 12 sitesin 2 countries
- Study dates
- Mar 2003to Sep 2016
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Consecutive series of patients received S.E.S prostheses
Who may be able to join
- A pre-operative level of pain and function the same as for conventional joint replacement
- A likelihood of obtaining relief of pain and improved function
- Full skeletal maturity
- Ability to follow instructions
- Good general health for age
- Willing to return for follow-up evaluations
Who cannot join
- Glenohumeral joint infection, osteomyelitis
- Neuro-muscular complications
- Inability to co-operate with and complete the study
Trial locations and contacts
12 sites in 2 countries.
12 sites in 2 countries
France11 sites
Clinique Générale
Annecy
Clinique St Joseph
Chambéry
Centre Hospitalier Général
Dax
Clinique Chirurgicale Orthopédique A.D.R.
Maxéville
Clinique St Jean
Montpellier
IRCOS
Paris
Clinique St Martin
Pessac
Clinique Mutualiste
Saint-Etienne
Polyclinique de l'Atlantique
Saint-Herblain
Institut A. Tzanck
Saint-Laurent-du-Var
Institut Calot
Saint-Laurent-du-Var
About this study
Official title: A Prospective, Multicentre Study Evaluating the Clinical Performance of the S.E.S Shoulder Prosthesis
This observational study intends to collect efficacy and safety data on S.E.S shoulder system
Read the detailed description
The S.E.S.® shoulder system has been developed to provide a complete solution for all the indications for Shoulder Arthroplasty, Arthritis, Rotator Cuff Arthropathy, Proximal Humeral Fracture, minimising bone resection and restoring the natural anatomy of the patient.
- Conditions
- Arthritis
- Keywords
- Shoulder Replacement
- Medical subject headings
- Arthritis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| S.E.S prosthesis | Consecutive series of patients with a S.E.S prosthesis. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Constance and oxford Scores
Measured: 6m, 1yr, 2yr, 3yr, 4yr and 5 yr
Secondary outcomes (2)
Complication
Measured: Any time
Patient Satisfaction
Measured: 6m,1yr,2yr,3yr,4yr and 5yr
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2008 (estimated)
- Study startMar 2003
- Primary completionSep 2016
- Study completionSep 2016
Why it stopped: Product no more sold
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ArthritisStudies of the same condition, open and under way.
- More trials run by Zimmer BiometThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Zimmer Biomet
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Biomet France SARL
- Responsible party
- Sponsor
- Investigators
- Laurent BEGUIN, MD, Principal investigator, Centre hospitalier Bellevue
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00754416
- Sponsor's protocol ID
- BMET FR 02
- Status last verified
- Mar 2017
- First submitted
- 16 Sep 2008
- Last updated
- 7 Mar 2017
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 Mar 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Multicentre Study Evaluating the Clinical Performance of the S.E.S Shoulder Prosthesis
- ClinicalTrials.gov ID
- NCT00754416
- Acronym / sponsor ID
- BMET FR 02
- Conditions
- Arthritis
- Keywords
- Shoulder Replacement
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: Product no more sold
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Zimmer BiometIndustry (pharma, biotech, devices)
- Collaborators
- Biomet France SARL
- Study start
- Mar 2003
- Primary completion
- Sep 2016 (actual)
- Study completion
- Sep 2016 (actual)
- First posted
- 18 Sep 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This observational study intends to collect efficacy and safety data on S.E.S shoulder system
Detailed description
The S.E.S.® shoulder system has been developed to provide a complete solution for all the indications for Shoulder Arthroplasty, Arthritis, Rotator Cuff Arthropathy, Proximal Humeral Fracture, minimising bone resection and restoring the natural anatomy of the patient.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| S.E.S prosthesis | – | –Consecutive series of patients with a S.E.S prosthesis. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Consecutive series of patients received S.E.S prostheses
Key inclusion criteria (6 listed)
- A pre-operative level of pain and function the same as for conventional joint replacement
- A likelihood of obtaining relief of pain and improved function
- Full skeletal maturity
- Ability to follow instructions
- Good general health for age
Key exclusion criteria (3 listed)
- Glenohumeral joint infection, osteomyelitis
- Neuro-muscular complications
- Inability to co-operate with and complete the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Constance and oxford Scores
Time frame: 6m, 1yr, 2yr, 3yr, 4yr and 5 yr
2 secondary outcomes
Complication
Time frame: Any time
Patient Satisfaction
Time frame: 6m,1yr,2yr,3yr,4yr and 5yr
Results and safety
The study was stopped early (reason given: Product no more sold). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Mar 2017.
Related trials for Arthritis
Not yet recruiting
MYTP01 for Immune-Mediated Diseases
IgA Nephropathy, Kidney Transplant Recipients
Recruiting
Autologous Adipose-Derived Stem Cell Injections for Knee Osteoarthritis
Osteoarthritis, Knee
RecruitingPhase 2
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
Sjögren's Disease
Recruiting
Exploration of Appropriate BIS Range and Propofol Effect-site Concentration During Total Intravenous Anesthesia With Concomitant Adjuvants.
Knee Osteoarthritis, Replacement, Knee
Not yet recruiting
Platelet-Rich Plasma, Hyaluronic Acid, or Their Combination for Knee Osteoarthritis in Athletes
Knee Osteoarthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Laurent BEGUIN, MD principal investigator
Centre hospitalier Bellevue
12 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Arthritis, run by Zimmer Biomet at 12 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 7 Mar 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 12 sites in France, Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Product no more sold). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Constance and oxford Scores (time frame: 6m, 1yr, 2yr, 3yr, 4yr and 5 yr). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Mar 2017.